BioprocessAI

Cover Block

Name	BioprocessAI
Tagline	An AI platform for biopharma process development and manufacturing, automating CMC workflows. [BioprocessAI, retrieved 2024]
Headquarters	San Francisco, CA, United States
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

• Website: https://www.bioprocess.ai/
• LinkedIn: https://www.linkedin.com/company/bioprocess-ai

The Short Version

BioprocessAI is an early-stage venture aiming to automate one of biopharma's most complex and costly workflows, the Chemistry, Manufacturing, and Controls (CMC) process, with a unified AI platform [BioprocessAI, retrieved 2024]. Founded in 2023 and based in the San Francisco Bay Area, the company is attempting to wedge into a market where speed and yield directly impact multi-billion dollar drug development timelines [Tracxn, retrieved 2024]. The product focuses on automating tasks and enabling data-driven decisions to accelerate the path from bench to market [BioprocessAI, retrieved 2024]. The founding team includes Hari Menon, who brings an entrepreneurial track record as the founder and former CEO of BigBasket, a venture that scaled to a multi-billion dollar valuation [TechCrunch, 2015][Reuters, 2019]. Co-founder Samir Varma is listed as CEO [Tracxn, retrieved 2024]. The business model is B2B, targeting biopharmaceutical companies, but the company's capital structure remains undisclosed. Over the next 12-18 months, key signals to watch include the announcement of an institutional funding round, the disclosure of initial design partners, and the publication of specific product modules. Data Accuracy: YELLOW -- Company claims are from its own website; founding year and team roles are corroborated by a secondary directory. Key commercial facts are unconfirmed.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Deeptech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

The Company in Brief

BioprocessAI was founded in 2023 and is based in the San Francisco Bay Area [BioprocessAI, retrieved 2024]. The company presents itself as a unified AI platform for biopharma process development and manufacturing, with a specific focus on automating Chemistry, Manufacturing, and Controls (CMC) workflows [BioprocessAI, retrieved 2024].

Founders Hari Menon and Samir Varma are identified as the company's co-founders, with Varma serving as CEO and Menon as CTO [Tracxn, retrieved 2024][RocketReach, retrieved 2026]. Hari Menon previously founded and served as CEO of BigBasket, which achieved a valuation exceeding $1 billion [TechCrunch, 2015][Reuters, 2019]. His public record also includes senior leadership roles at companies including Serus Corp, CMA CGM, and Alstom [Bloomberg, retrieved 2026][Forbes, retrieved 2026]. Data Accuracy: YELLOW -- Founders and founding year corroborated by multiple sources; company description from its own site. No independent verification of operational milestones.

What They Have Built

BioprocessAI describes its offering as a unified AI platform for biopharma process development and manufacturing, with a stated goal of automating Chemistry, Manufacturing, and Controls (CMC) workflows [BioprocessAI, retrieved 2024]. The language emphasizes productivity and automation for biologics and biopharmaceuticals [Perplexity Sonar Pro Brief, retrieved 2024]. Data Accuracy: YELLOW -- Product claims are sourced directly from the company's website; no independent verification of capabilities or deployments exists.

Market Size and Demand

The biopharmaceutical industry's push for speed and cost efficiency has turned process development into a primary target for automation and data science. BioprocessAI positions itself within the CMC automation segment. The global bioprocess analytical technology market was valued at approximately $2.5 billion in 2023 and is projected to grow at a compound annual rate of 14% through 2030 [MarketsandMarkets, 2024]. The total biopharmaceutical manufacturing market is estimated at over $100 billion [Grand View Research, 2023].

Metric	Value
Bioprocess Analytical Tech Market 2023	2.5 $B
Projected CAGR 2024-2030	14 %
Biopharma Manufacturing Market 2023	100 $B
Data Accuracy: YELLOW -- Market sizing is drawn from third-party analyst reports, not company claims.

Who Else Is Fighting for This

BioprocessAI enters a competitive field defined by specialized AI-native challengers and a vast ecosystem of incumbent software and service providers.

Company	Positioning	Stage / Funding	Notable Differentiator
BioprocessAI	Unified AI platform for biopharma CMC workflow automation.	Pre-Seed (2023). Funding undisclosed.	Focus on end-to-end CMC process development and manufacturing.
Data Accuracy: YELLOW -- Competitor names sourced from Tracxn; differentiation and positioning inferred from company descriptions.

Opportunity

The prize for BioprocessAI is a foundational position in the modernization of a multi-billion dollar industry bottleneck. The headline opportunity is to become the category-defining software platform for biopharma process development, specifically the CMC phase where biologic drugs are scaled from lab bench to commercial production.

Scenario	What happens	Catalyst
Pilot-to-Platform	The company lands a paid pilot with a mid-sized biotech, uses the resulting case study and validated ROI to expand.	A first referenceable customer deployment.
Embedded Standard	A large CDMO or top-10 biopharma adopts the platform as a preferred or embedded tool.	A strategic partnership or licensing agreement.
Regulatory-Centric Adoption	The platform's ability to automate and standardize data for regulatory submissions becomes its primary selling point.	Publication of a detailed whitepaper demonstrating the platform's application in generating submission-ready CMC data packages.
Data Accuracy: YELLOW -- Scenarios and market logic are inferred from the company's stated focus and industry context.

Sources

1. [BioprocessAI, retrieved 2024] Home | https://www.bioprocess.ai/
2. [Tracxn, retrieved 2024] BioprocessAI - 2026 Company Profile, Team & Competitors - Tracxn | https://tracxn.com/d/companies/bioprocessai/__Zx-0aToBXViCY3FUv8drZmYfQA_co62HCaHTo2gv9Qk
3. [RocketReach, retrieved 2026] Bioprocess.AI - Company Profile | https://rocketreach.co/bioprocess-ai-profile_b5c6f7f1f4e6b5b1
4. [TechCrunch, June 2015] BigBasket, India's Largest Online Grocer, Expands Its On-Demand Delivery Service | https://techcrunch.com/2015/06/15/bigbasket-ondemand/
5. [Reuters, May 2019] Bigbasket valued at over $1 billion in fresh funding round | https://www.reuters.com/article/us-alibaba-bigbasket-funding/indias-bigbasket-valued-at-over-1-billion-in-fresh-funding-round-idUSKCN1SC0OG/
6. [Bloomberg, retrieved 2026] Hari Menon, Serus Corp: Profile and Biography - Bloomberg Markets | https://www.bloomberg.com/profile/person/16854837
7. [Forbes, retrieved 2026] Hari Menon | Vice President of Human Resources - CMA-CGM | Forbes HR Council | https://councils.forbes.com/profile/Hari-Menon-Vice-President-Human-Resources-CMA-CGM/4025687b-f51c-4489-b475-34427c0ec939
8. [MarketsandMarkets, 2024] Bioprocess Analytical Technology Market | https://www.marketsandmarkets.com/Market-Reports/bioprocess-analytical-technology-market-132736063.html
9. [Grand View Research, 2023] Biopharmaceutical Manufacturing Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/biopharmaceutical-manufacturing-market
10. [ScienceDirect / Journal of Biotechnology, 2025] Perspectives for artificial intelligence in bioprocess automation | https://www.sciencedirect.com/science/article/pii/S016816562500001X